v3.26.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of amounts were recognized within revenue

Three Months Ended March 31, 

(In thousands)

2026

2025

Viatris collaboration agreement – Amounts receivable from Viatris

$

17,699

$

15,388

 

Schedule of implied share of total net sales

Three Months Ended March 31, 

(In thousands)

  ​

2026

  ​

2025

  ​ ​ ​

YUPELRI net sales (Theravance Biopharma implied 35%)

$

21,851

$

20,420